On March 24, 2025, Tonix Pharmaceuticals Corp. (NASDAQ:TNXP) announced that the FDA will not require an Advisory Committee (AdCom) meeting regarding the New Drug Application (NDA) for TNX-102 SL ...

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the AAPM 2025 Annual Meeting, held April 3-6, 2025, in Austin, Texas.

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia TNX-102 SL demonstrated statistically significant ...

Tonix Pharmaceuticals Holding Corp. announced that the FDA has set a PDUFA goal date of August 15, 2025, for TNX-102 SL, which, if approved, would be the first new drug for fibromyalgia in over 15 ...

TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Commercial planning for TNX-102 SL underway for launch ...

The biopharmaceutical company said that, if approved, TNX-102 SL tablets would be the first new treatment option for fibromyalgia patients in 15 years. The FDA previously granted Fast Track ...

Tonix Pharmaceuticals shares were up 51% at $34.67 after the company said the Food and Drug Administration will not require an advisory committee meeting to discuss a New Drug Application for TNX ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company, presented data at the AAPM 2025 Annual Meeting showing that its ...

(MENAFN- GlobeNewsWire - Nasdaq) August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating ...